Fig. 4
From: Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer
ROC curve analysis of the marker panel alone compared to marker panel plus “standard of care” pathology variables. a The analysis demonstrates cumulative sensitivity and specificity of four markers with an AUC = 0.78, OR (CI) = 6.56 (2.98, 14.40), selected as ideal biomarkers for a prognostic test. b ROC analysis shows the combined sensitivity and specificity of four markers along with the pathological/clinical features increasing the AUC = 0.89 and OR (CI) = 12.47 (4.85, 32.05) representing an enhanced prognostic test. 1-MA 1-methyladenosine, APOA-IV apolipoprotein A-IV, AUC area under curve, GLS gleason score, OR odds ratio, TNC Tenascin C